Treatment

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management

Pulmonary hypertension (PH) is a chronic condition that is characterised by elevated pulmonary vascular pressures and can be caused by several disease processes (see Table 1).1 Regardless of the aetiology, PH is a progressive disease with a clinical course characterised by frequent decompensations in advanced stages and often a poor prognosis despite the development of novel therapeutic agents.2 AF and atrial flutter are common in PH popul